Fisher Company of ThermoFisher Scientific is responsible for the affairs of market, strategy, brand and product line management in China. Now he lives in Shanghai. Prior to this, he worked in Market Department of American Applied Biosystems Co., Ltd.
Shi Lei started his career by working on regional sales for American Bio-rad in 1996, afterwards, he joined American Applied Biosystems Co., Ltd where he held many positions including those responsible for sales and market. He obtained bachelor's degree in Biochemistry in Fudan University and MBA in Shanghai University of Finance and Economics.

◎ Philippe Destremont is a member of Expert Network in Technip Organisation.He is a member of A3P, an Organisation of Experts working for sterile products.
◎ Philippe is one of the Technip senior experts since 9 years in charge of sterile drug product facilty design and organisation. He has been involved in many sterile projects for major pharmaceutical companies and in various fields such as biotech products vaccines, blood products separation and purification.
◎ Before doing engineering, Philippe has spent 10 years as sterile products production manager in several companies in Europe.

November, 2008 —General Manager of Tianjin Tasly Sants Pharmaceutical Co., Ltd
January, 2007 — October, 2008 Quality Director of GlaxoSmithKline(Tianjin)
She served as the leader of Quality Department composed of about 50 employees. She led relevant departments of the Company to successfully pass the certification of EU MHRA Quality System.
2005 — 2006 Quality Management Manager of Singapore Schering Plough
2002 —2005 Quality Law and Regulation & Quality System Manager of Singapore Schering Plough
2001 — 2002 Senior Quality Director of Singapore Schering Plough
1999 — 2001 Process chemist of Singapore Schering Plough
1997 — 1999 R&D chemist of Singapore Schering Plough
She joined Schering Plough at the initial stage of building factory and participated in many construction projects (raw materials, sterile preparations, tablets and spraying agents) in Singapore and has working experience in research and development, introduction of new medicines into market, production, engineering, quality, international auditing and validation etc, and worked on or directed efforts in quality system (EU EMEA, U.S FDA, other countries') certification of the Company for many times and participated in the construction of SAP system of the Company during which she was sent as key talent of the Company to America for study. She has scored achievements in both theory and practice of enterprise management.

Senior Partner. David Begg Associates. UK
◎ Martin has over 30 years experience in the pharmaceutical and healthcare industry. He has conducted audits and education programs for many hundreds of companies in over 25 countries
◎ A microbiologist by profession, Martin has considerable experience in the Manufacture, Quality Assurance and Testing of aseptic products. He is also qualified to act as a ‘Qualified Person' within the EU
◎ Martin is passionate about ‘Continuous Quality Improvement' in the pharmaceutical industry.

Mr. Jaskolski joined M+W Zander in 1990.Before joining M+W Zander, he worked for ROM and Biprohut for 7 years.
Mr. Jaskolski has over 20 years of professional experience in Engineering and Project Management for Microelectronics and Phamaceutical industries. It is worth especially mentioning that Mr.Jaskolski has served as the project leader in CPGJ Shanghai、Mundi pharma Beijing、Shanghai Roche Pharmaceuticals、Braun Suzho、Fusogen Tianjin, and gotten rich experience in local project managment.

Over 20 years' experience in fine chemicals and pharmaceutical field as a mechanical engineer; notably in the pharmaceutical field covering aseptic, oral dosage and API areas.
In Aseptic Bulk Powder & Containment Project, major activities were as follows: Finalization of material handling flow in plant；Optimization of containment facilities；Selection of liquid/solid separator and drying machine；In aseptic process, design of automatic filling line system for vial, ampoule and syringe handling.

Has over 9 years of professional experience in Pharmaceutical Industry, especially in Validation and Quality Management.
Be familiar with Chinese, USA and EU GMP Regulations and Guidance.
Experience in GMP training and validation (such as HVAC system qualification, water system qualification, equipment qualification, cleaning validation, process validation etc.).
Experience in Production and Quality Management in Pharmaceutical Company.

Gearoid is PM Group's Commissioning and Qualification Manager for the Asia-Pacific region. Located in Singapore, Gearoid manages our Commissioning and Qualification business throughout Asia with a special focus on Singapore, China and India.
Gearoid has worked all his life in the Life Science sector in Europe, Asia and Australia, and has built up an excellent track record in the Commissioning, Validation and Qualification of Life Science facilities including Biopharma, Chemical API and Secondary manufacturing facilities.
Gearoid has experience in FDA and EMEA regulated facilities. Most recently, he oversaw the preparation of qualification documentation at GSK Biological's Biopharmaceutical facility in Singapore.

1997-2005 Senior Project Manager in Automation at NCPC (North China Pharmaceutical Group Corporation )
From 2005 to today Pharmaceutical Branch Manager at Automation and Drives Group of Siemens China

Responsibilities include keeping up-to-date with the latest regulatory requirement around the world and ensuring that Eurotherm solutions match the latest requirement of the regulatory bodies (e.g. 21 CFR Part 11, PAT).
Matt Safi is an active member of GAMP forum. He is a member of the GAMP's special group (Guideline for testing systems).

Ph . D of American University of Connecticut; an expert in pharmaceuticals research and development and management, clinical pharmacology and biopharmacy; former chief scientist and one of highest-level reviewers of metric clinical pharmacology of U.S Food and Drug Administration, member of U.S Federal Joint Committee of Asian Executives; currently, Vice-president of Tianjin Tasly Group, Director of U.S SunTech Research Institute, professor, doctoral supervisor and Faculty Director of Pharmacy Department of Tianjin University; concurrently specially invited scientist of U.S National Institutes of Health （NIH）, visiting professor of Medical School of Fudan University and Nutrition Department of Shanghai Institutes for Biological Sciences, senior researcher of Guangzhou Life Sciences Research Institute of Chinese Academy of Sciences and visiting professor of Medical Economics Research Center of Peking University etc.
Doctor Henry Sun has gathered rich experience in forging and operating strong alliance among domestic and foreign pharmaceutical enterprises. After returning home from abroad, he directed the team to complete the research, development of more than ten kinds of domestic new Chinese patent drugs, pharmaceutical chemicals and biopharmaceuticals and launch them in the market, all of which have been approved by China State Food and Drug Administration (SFDA) in the approval document concerning new drugs and production. Meanwhile, one Canadian approval document concerning the launch of traditional medicines in market, two U.S FDA approval documents and one Australian TGA approval document for clinical research on new medicines are obtained and three pharmaceutical intermediates are granted U.S DMF and European COS registration. Doctor Sun has successfully directed efforts to launch cooperative projects for Chinese enterprises, Indian Hetros Pharmaceutical Group, British COOP Group, American CureGen and Bay Capital and Hong Kong Morningside etc. He also made joint efforts in establishing China-Italy Joint Laboratory etc.